XML 34 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets (Tables)
 9 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets

The following table summarizes the gross book value, accumulated amortization and net book value balances of intangible assets as of September 30, 2022 and December 31, 2021 (in thousands):

 

   September 30, 2022  December 31, 2021
   Gross Book Value  Accumulated Amortization  Net Book Value  Gross Book Value  Accumulated Amortization  Net Book Value
Licensing Agreement(1)  $29,400   $21,096   $8,304   $29,400   $19,780   $9,620 
Trade names and trademarks   210    65    145    210    50    160 
Customer relationships   240    74    166    240    56    184 
Total intangible assets  $29,850   $21,235   $8,615   $29,850   $19,886   $9,964 
(1)Prior to the acquisition, Enteris entered into a non-exclusive commercial license agreement (the “License Agreement”) with Cara Therapeutics, Inc. (“Cara”), for oral formulation rights to Enteris’ Peptelligence® technology to develop and commercialize Oral KORSUVATM in any indication worldwide, excluding South Korea and Japan. Cara is obligated to pay Enteris certain development, regulatory and tiered commercial milestone payments, as well as low single-digit royalties based on net sales in the licensed territory.
[custom:DisclosureIntangibleAssetsDetailsAbstract]
   September 30, 2022  December 31, 2021
   Gross Book Value  Accumulated Amortization  Net Book Value  Gross Book Value  Accumulated Amortization  Net Book Value
Licensing Agreement(1)  $29,400   $21,096   $8,304   $29,400   $19,780   $9,620 
Trade names and trademarks   210    65    145    210    50    160 
Customer relationships   240    74    166    240    56    184 
Total intangible assets  $29,850   $21,235   $8,615   $29,850   $19,886   $9,964 
(1)Prior to the acquisition, Enteris entered into a non-exclusive commercial license agreement (the “License Agreement”) with Cara Therapeutics, Inc. (“Cara”), for oral formulation rights to Enteris’ Peptelligence® technology to develop and commercialize Oral KORSUVATM in any indication worldwide, excluding South Korea and Japan. Cara is obligated to pay Enteris certain development, regulatory and tiered commercial milestone payments, as well as low single-digit royalties based on net sales in the licensed territory.
Schedule of Intangible Asset Amortization Expense

The estimated future amortization expense related to intangible assets as of September 30, 2022 is as follows (in thousands):

 

 
Intangible Assets (Details 2)
Fiscal Year  Amount
Remainder of 2022  $426 
2023   1,703 
2024   1,546 
2025   1,076 
2026   1,076 
Thereafter   2,788 
Total  $8,615